This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Agency for Science, Technology and Research, National University of Singapore. Active years: 2020-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2020-2026
Title: Joo Leng Low: Inventor in Biomedical Research.
Introduction
Joo Leng Low is an inventor associated with biomedical research in Singapore. Her work includes patent inventions concerning compounds that modulate biological pathways and methods for differentiating stem cells into cardiomyocytes. The supplied information lists 2 patents.
Latest Patents
“ Heterocyclic Compounds as Modulators of Beta-Catenin / TCF4 Interaction” describes compounds and methods for inhibiting β-catenin or disrupting its interaction with T-cell factor 4. The disclosed approaches are intended to support the treatment of conditions including cancer, neurodegenerative diseases, metabolic and cardiovascular diseases, fibrosis, and bone diseases.
“2,4,5-Tri-Substituted Azole-Based Casein Kinase 1 Inhibitors as Inducers for Cardiomyogenesis” concerns methods for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes through casein kinase 1 inhibition. The invention also describes using the method during later stages of stem-cell differentiation, combining inhibitors with other small molecules, and providing compounds and kits for stem-cell differentiation.
Career Highlights
The supplied career information associates Low with Singapore’s Agency for Science, Technology and Research and the National University of Singapore. Her listed patent work spans small-molecule research and stem-cell differentiation.
Collaborations
The supplied information identifies Steve Oh and Qixing Zhong as Low’s coworkers.
Conclusion
Joo Leng Low’s listed inventions address potential therapeutic applications of beta-catenin modulation and methods for producing cardiomyocytes from pluripotent stem cells.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile